KR20060120193A - 액체 제형내 토피라메이트의 제어된 방출 - Google Patents

액체 제형내 토피라메이트의 제어된 방출 Download PDF

Info

Publication number
KR20060120193A
KR20060120193A KR1020067011334A KR20067011334A KR20060120193A KR 20060120193 A KR20060120193 A KR 20060120193A KR 1020067011334 A KR1020067011334 A KR 1020067011334A KR 20067011334 A KR20067011334 A KR 20067011334A KR 20060120193 A KR20060120193 A KR 20060120193A
Authority
KR
South Korea
Prior art keywords
formulation
topiramate
layer
drug
liquid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020067011334A
Other languages
English (en)
Korean (ko)
Inventor
샤오링 리
앤드류 람
리앙 동
Original Assignee
알자 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알자 코포레이션 filed Critical 알자 코포레이션
Publication of KR20060120193A publication Critical patent/KR20060120193A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020067011334A 2003-11-14 2004-11-12 액체 제형내 토피라메이트의 제어된 방출 Withdrawn KR20060120193A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51995803P 2003-11-14 2003-11-14
US60/519,958 2003-11-14

Publications (1)

Publication Number Publication Date
KR20060120193A true KR20060120193A (ko) 2006-11-24

Family

ID=34619401

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020067011334A Withdrawn KR20060120193A (ko) 2003-11-14 2004-11-12 액체 제형내 토피라메이트의 제어된 방출

Country Status (13)

Country Link
US (1) US20050129765A1 (cg-RX-API-DMAC7.html)
EP (1) EP1684713A1 (cg-RX-API-DMAC7.html)
JP (1) JP2007511519A (cg-RX-API-DMAC7.html)
KR (1) KR20060120193A (cg-RX-API-DMAC7.html)
CN (1) CN1905857A (cg-RX-API-DMAC7.html)
AU (1) AU2004291081A1 (cg-RX-API-DMAC7.html)
CA (1) CA2545834A1 (cg-RX-API-DMAC7.html)
IL (1) IL175605A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA06005462A (cg-RX-API-DMAC7.html)
NO (1) NO20062739L (cg-RX-API-DMAC7.html)
TW (1) TW200528144A (cg-RX-API-DMAC7.html)
WO (1) WO2005048981A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200604882B (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
MXPA06002067A (es) * 2003-08-22 2006-08-11 Johnson & Johnson Suministro gradual de topiramato durante periodo prolongado.
WO2005065648A2 (en) * 2003-12-29 2005-07-21 Alza Corporation, Inc., Novel drug compositions and dosage forms of topiramate
AU2004312082A1 (en) * 2003-12-29 2005-07-21 Alza Corporation, Inc. Novel drug compositions and dosage forms
MX2007014713A (es) * 2005-05-25 2008-02-14 Janssen Pharmaceutica Nv Formulacion pediatrica de topiramato.
WO2008027557A2 (en) * 2006-08-31 2008-03-06 Spherics, Inc. Topiramate compositions and methods of enhancing its bioavailability
EP2394643B1 (en) 2006-11-17 2015-09-02 Supernus Pharmaceuticals, Inc. Sustained-release formulations of topiramate
EP2363113B1 (en) * 2006-12-04 2017-08-02 Supernus Pharmaceuticals, Inc. Enhanced immediate release formulations of topiramate
EP2219624A2 (en) * 2007-11-08 2010-08-25 Glaxo Group Limited Pharmaceutical formulations
US20120145572A1 (en) * 2009-04-20 2012-06-14 Ecole Polytechnique Federale De Lausanne (Epfl) Containers assembled in fluid and corresponding production
CN102579367B (zh) * 2012-03-23 2014-03-12 中国人民解放军军事医学科学院毒物药物研究所 托吡酯缓释药物组合物、其制备方法及用途
CN103316026B (zh) 2012-03-23 2016-05-11 中国人民解放军军事医学科学院毒物药物研究所 含芬特明和托吡酯的联合产品及其制备方法
EP2829270B1 (en) 2012-03-23 2020-11-11 Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China Joint product containing synephrine and topiramate
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
CN108379588B (zh) * 2018-03-05 2024-07-02 合肥合源药业有限公司 托吡酯组合物
US20210169844A1 (en) 2019-12-10 2021-06-10 Tulex Pharmaceuticals Inc. Compositions and methods for treating epilepsy, seizures and other conditions
US12290504B2 (en) 2023-04-11 2025-05-06 Tap Pharmaceuticals Ag Aqueous formulations of topiramate

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2707154A (en) * 1952-06-09 1955-04-26 Monsanto Chemicals Antioxidants and compositions containing same
US3173876A (en) * 1960-05-27 1965-03-16 John C Zobrist Cleaning methods and compositions
NL271831A (cg-RX-API-DMAC7.html) * 1960-11-29
US3276586A (en) * 1963-08-30 1966-10-04 Rosaen Filter Co Indicating means for fluid filters
US3546142A (en) * 1967-01-19 1970-12-08 Amicon Corp Polyelectrolyte structures
CH508415A (de) * 1967-10-27 1971-06-15 Hoffmann La Roche Antioxydative Mischung und deren Verwendung
US3573936A (en) * 1967-12-15 1971-04-06 Rayonier Inc Plicatic acid and thiodipropionic acid as antioxidants for use in animal fats and vegetable oils
US3541006A (en) * 1968-07-03 1970-11-17 Amicon Corp Ultrafiltration process
US3541005A (en) * 1969-02-05 1970-11-17 Amicon Corp Continuous ultrafiltration of macromolecular solutions
US3865108A (en) * 1971-05-17 1975-02-11 Ortho Pharma Corp Expandable drug delivery device
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4002173A (en) * 1974-07-23 1977-01-11 International Paper Company Diester crosslinked polyglucan hydrogels and reticulated sponges thereof
US4077407A (en) * 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4038434A (en) * 1976-03-12 1977-07-26 Howard Hall & Company Antioxidant stabilized edible compositions
US4111201A (en) * 1976-11-22 1978-09-05 Alza Corporation Osmotic system for delivering selected beneficial agents having varying degrees of solubility
US4207893A (en) * 1977-08-29 1980-06-17 Alza Corporation Device using hydrophilic polymer for delivering drug to biological environment
US4200098A (en) * 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4259323A (en) * 1980-03-24 1981-03-31 Hoffmann-La Roche Inc. Potassium chloride emulsion
IN159370B (cg-RX-API-DMAC7.html) * 1982-01-15 1987-05-09 Ciba Geigy Ag
US4513600A (en) * 1983-01-03 1985-04-30 The Minster Machine Company Cam actuated ejector for a shell press
US4783337A (en) * 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US4513006A (en) * 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
US4627850A (en) * 1983-11-02 1986-12-09 Alza Corporation Osmotic capsule
US4663148A (en) * 1984-03-21 1987-05-05 Alza Corporation Dispenser comprising telescopically engaging members
US4915949A (en) * 1987-07-13 1990-04-10 Alza Corporation Dispenser with movable matrix comprising a plurality of tiny pills
US5024842A (en) * 1988-04-28 1991-06-18 Alza Corporation Annealed coats
US4931285A (en) * 1988-04-28 1990-06-05 Alza Corporation Aqueous based pharmaceutical coating composition for dosage forms
US5006346A (en) * 1988-04-28 1991-04-09 Alza Corporation Delivery system
CA1340821C (en) * 1988-10-06 1999-11-16 Nobuyuki Fukazawa Heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components
US5126142A (en) * 1989-07-18 1992-06-30 Alza Corporation Dispenser comprising ionophore
US5324280A (en) * 1990-04-02 1994-06-28 Alza Corporation Osmotic dosage system for delivering a formulation comprising liquid carrier and drug
US5190765A (en) * 1991-06-27 1993-03-02 Alza Corporation Therapy delayed
US5252338A (en) * 1991-06-27 1993-10-12 Alza Corporation Therapy delayed
AU651244B2 (en) * 1991-09-19 1994-07-14 Mcneilab, Inc. Process for the preparation of chlorosulfate and sulfamate derivatives of 2,3:4,5-bis-0-(1-methylethylidene)-beta-D- fructopyranose and (1-methylcyclohexyl)methanol
US5643909A (en) * 1993-04-19 1997-07-01 Syntex (U.S.A.) Inc. 10,11-Methanodibenzosuberane derivatives
ZA953078B (en) * 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
US5633011A (en) * 1994-08-04 1997-05-27 Alza Corporation Progesterone replacement therapy
US5614578A (en) * 1994-10-28 1997-03-25 Alza Corporation Injection-molded dosage form
US5824638A (en) * 1995-05-22 1998-10-20 Shire Laboratories, Inc. Oral insulin delivery
US6551613B1 (en) * 1998-09-08 2003-04-22 Alza Corporation Dosage form comprising therapeutic formulation
US6174547B1 (en) * 1999-07-14 2001-01-16 Alza Corporation Dosage form comprising liquid formulation
DE69915346T2 (de) * 1998-12-17 2004-07-22 Alza Corp., Mountain View Umwandlung von flüssigkeitsgefüllten gelatinkapseln in systeme mit gesteuerter wirkstoffabgabe durch mehrfache beschichtungen
US6342249B1 (en) * 1998-12-23 2002-01-29 Alza Corporation Controlled release liquid active agent formulation dosage forms
US6559293B1 (en) * 2002-02-15 2003-05-06 Transform Pharmaceuticals, Inc. Topiramate sodium trihydrate
DE60322371D1 (de) * 2002-03-29 2008-09-04 Alza Corp Volumensparende arzneiform zur kontrollierten freisetzung
US20070243254A1 (en) * 2002-06-26 2007-10-18 David Edgren Novel drug compositions and dosage forms of topiramate
EP1534238A1 (en) * 2002-07-29 2005-06-01 ALZA Corporation Formulations and dosage forms for controlled delivery of topiramate

Also Published As

Publication number Publication date
JP2007511519A (ja) 2007-05-10
IL175605A0 (en) 2006-09-05
US20050129765A1 (en) 2005-06-16
TW200528144A (en) 2005-09-01
ZA200604882B (en) 2007-11-28
AU2004291081A1 (en) 2005-06-02
CN1905857A (zh) 2007-01-31
WO2005048981A1 (en) 2005-06-02
CA2545834A1 (en) 2005-06-02
NO20062739L (no) 2006-08-14
MXPA06005462A (es) 2006-12-15
EP1684713A1 (en) 2006-08-02

Similar Documents

Publication Publication Date Title
KR100634069B1 (ko) 다중 코팅에 의한, 액체 충진 젤라틴 캡슐로부터 제어방출 시스템으로의 전환
US8475813B2 (en) Methods of treatment using a gastric retained gabapentin dosage
KR101365031B1 (ko) 오피오이드 서방성 경구 제형을 위한 알코올­유도 용량덤핑의 감소 방법
US20110195981A1 (en) Methods and dosage forms for reducing side effects of benzisozazole derivatives
US20050129765A1 (en) Controlled release of topiramate in liquid dosage forms
MXPA05001184A (es) Formulaciones y formas de dosificacion para administracion controlada de topiramato.
KR20060123219A (ko) 레보도파 및 카르비도파의 투여
JP2005535682A (ja) パリペリドンを制御送達する方法および投薬形態物
KR100738276B1 (ko) 항바이러스성 약제
US20090227605A1 (en) Enhanced efficacy benzisoxazole derivative dosage forms and methods
US20070004797A1 (en) Methods and dosage forms for reducing side effects of carbamate compounds
US20060257484A1 (en) Combination of tramadol and substances that comprise gabapentin
MXPA06002067A (es) Suministro gradual de topiramato durante periodo prolongado.
US20070298105A1 (en) Methods of treating conditions by sustained release administration of benzimidazole derivatives
WO2006085856A1 (en) Methods and dosage forms for reducing side effects of benzisozazole derivatives
CA2554874A1 (en) Methods of reducing alcohol-induced dose dumping for hydromorphone sustained release oral dosage forms
JP2006522016A (ja) 改変された粘度の層を用いる方法および投薬形態物
HK1106451B (en) Methods of reducing alcohol-induced dose dumping for opioid sustained release oral dosage forms

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20060609

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid